Company Description
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.
In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services.
The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents.
Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
| Country | Germany |
| IPO Date | Sep 19, 1996 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| Employees | 119,845 |
| CEO | Ms. Helen Giza |
Contact Details
Address: Else-kroener Strasse 1 Bad Homburg, 2M 61352 Germany | |
| Phone | 011-49-6172-6090 |
| Website | freseniusmedicalcare.com |
Stock Details
| Ticker Symbol | FMS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001333141 |
| CUSIP Number | 358029106 |
| ISIN Number | US3580291066 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Helen Giza | Chief Executive Officer and Chair of Management Board of Fresenius Med. Care Mgmt AG |
| Martin Fischer | Chief Financial Officer and Member of the Management Board of Fresenius Medical Care Management AG |
| Dr. Franklin W. Maddux F.A.C.P. | Global Chief Medical Officer and Member of Management Board of Fresenius Medical Care Management AG |
| Dr. Katarzyna Mazur-Hofsab Ph.D. | Management Board Member for Care Enablement of Fresenius Medical Care Management AG |
| Craig Cordola FACHE, M.B.A., M.H.A. | Chief Executive Officer of Care Delivery and Member of Management Board |
| Dr. Dominik Heger | Executive Vice President and Head of Investor Relations, Strategic Development and Communications |
| Joachim Weith | Senior Vice President of Corporate Communications and Governmental Affairs |
| Dr. Gail-Suzanne Brown | Senior Vice President of Research and Development |
| Glenn Slater | Senior Vice President of Manufacturing and Supply Chain Operations |
| Dr. Wolfgang Kummerle | Senior Vice President - Quality Management International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | 6-K | Report of foreign issuer |
| Mar 13, 2024 | 6-K | Report of foreign issuer |
| Mar 5, 2024 | 6-K | Report of foreign issuer |
| Feb 20, 2024 | 6-K | Report of foreign issuer |
| Feb 20, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Feb 20, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 20, 2024 | 6-K | Report of foreign issuer |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | 6-K | Report of foreign issuer |
| Feb 5, 2024 | 6-K | Report of foreign issuer |